Baruch S. Blumberg Institute

DUBLIN--( BUSINESS WIRE )--The "Acquired Gene or Chromosome Alterations Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update" report has been added to ResearchAndMarkets.com's offering. Acquired Gene or Chromosome Alterations Pipeline Report provides comprehensive information about the Acquired Gene or Chromosome Alterations pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. This report offers extensive coverage of Acquired Gene or Chromosome Alterations under development, providing comprehensive insights into pipeline products, major players, developmental activities, clinical trial data, and recent developments in the segment/industry. Acquired Gene or Chromosome Alterations comprises of reagents employed for genetic testing to detect cancer causing/ related alterations, such as; k-ras, BRCA 1+2, Telomerase and HER-2/neu (human epidermal growth factor receptor 2). The report reviews the details of major pipeline products, including product descriptions, licensing and collaboration details, and other developmental activities related to Acquired Gene or Chromosome Alterations. It also lists all the pipeline projects involving major players engaged in the development of Acquired Gene or Chromosome Alterations. Coverage of pipeline products is based on various stages of development, ranging from Early Development to Approved/Issued stages, allowing readers to understand the progress of these products in the pipeline. Key clinical trial data related to ongoing trials specific to pipeline products in the Acquired Gene or Chromosome Alterations segment is provided, offering valuable insights into the clinical development of these products. Reasons to Buy Formulate significant competitor information, analysis, and insights to improve R&D strategies Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage Identify and understand important and diverse types of Acquired Gene or Chromosome Alterations under development Develop market-entry and market expansion strategies Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline In-depth analysis of the product's current stage of development, territory and estimated launch date Key Topics Covered: 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Acquired Gene or Chromosome Alterations Overview 3 Products under Development 3.1 Acquired Gene or Chromosome Alterations - Pipeline Products by Stage of Development 3.2 Acquired Gene or Chromosome Alterations - Pipeline Products by Territory 3.3 Acquired Gene or Chromosome Alterations - Pipeline Products by Regulatory Path 3.4 Acquired Gene or Chromosome Alterations - Pipeline Products by Estimated Approval Date 3.5 Acquired Gene or Chromosome Alterations - Ongoing Clinical Trials 4 Acquired Gene or Chromosome Alterations - Pipeline Products under Development by Companies 4.1 Acquired Gene or Chromosome Alterations Companies - Pipeline Products by Stage of Development 4.2 Acquired Gene or Chromosome Alterations - Pipeline Products by Stage of Development 5 Acquired Gene or Chromosome Alterations Companies and Product Overview 6 Acquired Gene or Chromosome Alterations- Recent Developments 7 Appendix A selection of companies mentioned in this report includes Abital Pharma Pipelines Ltd Admera Health LLC Agena Bioscience Inc Aix-Marseille University Albert Ludwigs University of Freiburg Apteryx Imaging Inc Baruch S. Blumberg Institute Baylor College of Medicine bioMerieux SA Biotype Innovation GmbH Blondin Bioscience, LLC Cardiff Oncology Inc Cepheid Inc Children's Hospital Los Angeles Children's Hospital of Philadelphia China Medical Technologies Inc (Inactive) Chronix Biomedical Inc Columbia University Duke University Empire Genomics LLC Fred Hutchinson Cancer Research Center French National Institute of Health and Medical Research Garvan Institute of Medical Research Gencurix Inc Genetag Technology, Inc Genomic Health Inc GenomicTree Co Ltd German Cancer Research Center H. Lee Moffitt Cancer Center & Research Institute Inc Heali Ltd Hebrew University of Jerusalem Heidelberg Pharma AG Helmholtz Centre for Infection Research Inform Genomics Inc Institute of Cancer Research Interpace Biosciences Inc iTP Biomedica Corp Johns Hopkins University Massachusetts General Hospital Mayo Clinic McGill University MDNA Life Sciences Inc MolecularMD Corp Myriad International GmbH Nel ASA Northern California Institute for Research and Education NucleoBio Inc Ohio State University OmicsWay Corp Oxford Biodynamics Plc Oxford Cancer Biomarkers Ltd Pennsylvania State University Princess Margaret Cancer Centre QuantuMDx Group Ltd Queen's University Belfast Rosetta Genomics Ltd (Inactive) Stanford University Stony Brook University Syamala Srinivasa Life Sciences Pvt. Ltd Telo Genomics Corp The Chinese University of Hong Kong The University of New South Wales press Limited The Walter and Eliza Hall Institute of Medical Research TheraDiag SA Therawis Diagnostics GmbH Thrive Earlier Detection Corp Total Brain Ltd Trinity College Dublin University College London University of California San Diego University of Cambridge University of Central Florida University of Cologne University of Copenhagen University of Hawaii at Manoa University of Montreal University of Rochester University of South Carolina University of Southern California University of Strathclyde University of Sydney University of Texas Medical Branch at Galveston University of Washington Vyant Bio Inc Wistar Institute Yaathum Biotech Pvt Ltd Yale University For more information about this report visit https://www.researchandmarkets.com/r/fb39kc About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CHICAGO, July 13, 2023 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) is pleased to announce the appointment of Calvin Harris Jr., CPA and Joel D. Rosen, Esq. to the FSR Board of Directors. "We are thrilled to welcome Calvin and Joel to the FSR Board of Directors," said Dr. Louise Perkins, FSR Board President. "Calvin and Joel bring extraordinary passion, leadership and professional experience that will be an asset to both the Board and FSR towards our mission of improving the lives of those impacted by sarcoidosis and pursuit of a cure." Calvin Harris joins the FSR Board with extensive finance and accounting experience. He is the Chief Executive Officer of the New York State Society of CPAs, the oldest membership organization in the certified public accounting profession. Harris was diagnosed with sarcoidosis in 2014, but despite his disease, strives to live a life in service of others. Harris is an active member of the FSR community. He serves on the FSR Patient Advisory Committee, and the FSR Ignore No More: ACTe Now Advisory Committee and was a presenter at the recent FSR Crystal Gala Awards. Harris writes a twice-monthly column for Sarcoidosis News, called “Run Your Own Race.” The title is inspired by his newfound love of running, something his first pulmonary sarcoidosis doctor said was impossible for him, yet current doctors encouraged. He hopes his column reminds other sarcoidosis patients that their journey is their own race to run. Harris grew up in Maryland, near Washington, DC, and now lives in Brooklyn, New York. “As a sarcoidosis patient who has personally benefited from FSR, I am excited and honored to join the Board of Directors. The work FSR does is so important to so many, and through the work of FSR, I hope that one day sarcoidosis will be no more,” says Harris. Joel D. Rosen, Esq, is a managing partner and corporate lawyer at High Swartz located in Norristown, PA, with over 30 years of experience. Rosen’s practice areas include franchise law, business, commercial law, employment law, trademark/copyright law, and commercial leasing. Rosen counsels numerous businesses with corporate and commercial transactions, including formation, mergers & acquisitions, licensing, sales, and financing projects. His corporate client base spans a broad spectrum of industries including biotechnology, franchises, weight-loss, food and restaurants, consumer products, media and entertainment, software, technology, and nonprofit organizations. Rosen has received many professional accolades including being selected to Pennsylvania Super Lawyers, 2017-present, and as a Five-Star Attorney - Suburban Life Magazine, 2022-present. Rosen has extensive board experience and presently serves on the Board of Directors of several nonprofit organizations, including The Hepatitis B Foundation - where he has served as Chairman of the Board since 2008, The Pennsylvania Biotechnology Center, The Baruch S. Blumberg Institute, and the Montgomery Bar Foundation. Rosen serves on FSR’s Development Committee and played a significant role in securing support for FSR’s Inaugural Sarcoidosis Crystal Awards Gala which took place in Washington, DC this spring. When asked why he was interested in serving on FSR’s Board of Directors, Rosen commented, “Einstein said ‘In the middle of difficulty lies opportunity.’ Being diagnosed with sarcoidosis was certainly difficult, but joining FSR’s Board provides me with an opportunity to make a difference in fighting this disease.” FSR's Board of Directors is comprised of leaders from the business, medical, and patient communities. The Board is responsible for the strategic direction of the foundation. Together with the organization's Scientific Advisory Board (SAB), comprised of international sarcoidosis experts, they help advance FSR's mission by providing strategic advice on its scientific and research programs. About SarcoidosisSarcoidosis is a rare inflammatory disease characterized by the formation of granulomas—tiny clumps of inflammatory cells—in one or more organs of the body. Despite increasing advances in research, sarcoidosis remains difficult to diagnose with limited treatment options and no known cure. About the Foundation for Sarcoidosis Research (FSR)The Foundation for Sarcoidosis Research (FSR) is the leading international organization dedicated to finding a cure for sarcoidosis and improving care for sarcoidosis patients through research, education, and support. Since its establishment in 2000, FSR has fostered over $6 million in sarcoidosis-specific research efforts. For more information and to join our community, visit www.stopsarcoidosis.org. Contact:Cathi Davis312-341-0500 ext. 106cathi@stopsarcoidosis.org A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ef7ebaeb-ee56-4390-bb1a-421ed71ccdb1

点击这里，与几百位朋友们欢聚CMC高峰论坛！编者按：近几个月Hepatitis B Foundation网站乙肝新药表单未见更新，为帮助大家更准确地获取全球乙肝新药最前沿信息，肝霖君查询各大药企官网更新的产品管线信息和相关网络资料中的乙肝新药报道做了系统地整理，并汇总了慢乙肝新药与新药联合、新药与现有药物联合治疗的临床研究进展。本期表单更新有：新增处于临床I期的单克隆抗体162。新增处于临床前阶段的单克隆抗体N6HB426-20，衣壳抑制剂BA-53038B、HEC72702和SHR5133，双特异性抗体UM06。PAPD5/7抑制剂GSK3965193进入I/II期临床，衣壳抑制剂LW-231进入I期临床，小分子DF-006进入I期临床。新药联合治疗的探索明显加速，包括新药与新药联合、新药与现有药物的联合。许多新药单药在I期或II期研究中未达到主要疗效目标，企业便积极开始了不同联合治疗方案的探索。这也将是未来乙肝全面临床治愈的必要策略。新药相关联合用药临床研究汇总部分新药进展01N6HB426-20N6HB426-20是日本理化研究所研发的一款NTCP靶向单克隆抗体，可抑制HBV进入肝细胞，目前处于临床前研究阶段。02LW-231上海长森药业开发的小分子衣壳抑制剂LW-231于2022年3月1日首次获批临床，目前I期临床已经启动（CTR20221609），旨在评价LW-231片在健康受试者、慢性乙型肝炎患者中的耐受性、药代动力学及药效学。03BA-53038BBA-53038B是由Baruch S. Blumberg Institute开发的一款衣壳抑制剂，属于新型苯甲酰胺衍生物，目前处于临床前研究阶段。04HEC72702HEC72702是由东阳光药业开发的一款衣壳抑制剂，目前处于临床前研究阶段。相关手性研究显示，( R, R )-HEC72702对乙型肝炎病毒衣壳的抑制效力高于( R, S )-HEC72702。05SHR5133SHR5133是恒瑞医药开发的一款衣壳抑制剂，目前处于临床前研究阶段。06162162是养生堂开发的一款用于治疗慢性乙型肝炎的HBsAg中和抗体，目前I期临床（NCT05310487）正在招募当中，该项随机双盲、安慰剂对照试验旨在评估健康成人受试者接受单次递增剂量给药后的安全性、耐受性及药代动力学。07GSK3965193葛兰素史克研发的非典型poly（A）聚合酶5和7（PAPD5/7）小分子抑制剂GSK3965193进入I/II期临床（NCT05330455），该项首次人体研究分为4部分，第1、2部分旨在评估单剂量和多剂量GSK3965193在健康受试者中的安全性、耐受性和药代动力学，第3部分旨在评估GSK3965193降低慢乙肝患者HBsAg的能力，第4部分旨在评估 GSK3965193联合葛兰素史克另一反义寡核苷酸药物GSK3228836对慢乙肝患者的安全性、耐受性及疗效，目前正在招募中。08DF-006药物牧场研发的ALPK1激动剂DF-006进入I期临床（ACTRN12621000592842），该项随机双盲、安慰剂对照的首次人体研究旨在评估健康受试者口服单剂量和多剂量DF-006后的安全性、耐受性和药代动力学。09UM06UM06是优迈生物开发的一款双特异性抗体，目前处于临床前研究阶段。2020年12月15日，优迈生物与天境生物（杭州）签约，双方将合作进行UM06在抗肿瘤和慢乙肝治疗方面的研发。10TQA3334 + ETV ± TQB2450TQA3334和TQB2450分别是由正大天晴药业开发的TLR7激动剂和全人源化抗PD-L1单克隆抗体，一项单中心、随机、前瞻性、开放标签II期研究（NCT04202653）旨在评估TQA3334 + ETV ± TQB2450联合疗法相比ETV单药治疗慢乙肝的疗效和安全性，目前暂未启动招募。注：部分信息参考小番健康、肝脏时间。原文题目：【新药进展】全球乙肝新药进展(更新至2022年9月，独家整理)封面图来源：123rf版权声明/免责声明本文为授权转载文章，版权归拥有者。仅供感兴趣的个人谨慎参考，非商用，非医用、非投资用。欢迎朋友们批评指正！衷心感谢！文中图片、视频为授权正版作品，或来自微信公共图片库，或取自公司官网/网络根据CC0协议使用，版权归拥有者。任何问题，请与我们联系（电话：13651980212。微信：27674131。邮箱：contact@drugtimes.cn）。衷心感谢！推荐阅读成功药早，时代要好！药时代敬祝广大朋友们节日快乐！请欣赏优美歌曲和文章！～～健艾仕生物STAT5抑制剂在新冠肺炎引起的炎症因子风暴的临床试验进展顺利卢煜明因无创检测获拉斯克奖，距离诺奖还远吗？卡脖子 or 被卡脖子？生物制药产业供应链「国产替代」，已经需要争分夺秒！三款重磅PARP遇挫，FDA再「出手」，NMPA「如何面对」？刷新OS数据！H药登上JAMA主刊，PD-1治疗小细胞肺癌重大突破！药企的安得广厦千万间肿瘤药全部扑街！FDA两天开了4场专家咨询委员会，竟然只有一款「粪便疗法」通过了...中国制药江湖「神曲」！~~ 继《PD-1之歌》之后，药时代拟推出《双抗之歌》 | 附：30+篇双抗主题好文章行业再现【淘金者】：我就再赌最后一把！三院士齐聚！以临床价值为导向，打造生物医药源头创新机制 | 上海源创新药高峰论坛圆满落幕！阿尔茨海默病，可能是我们老去后的结局……RSV领域时隔60年起风云！阿斯利康/赛诺菲，一剂绝尘！罗永庆离开腾盛博药加盟云顶新耀，中国药企挖人大战进入白热化。这是行业成熟的标志吗？请投票！点击这里，报名参加第三届中国新药CMC高峰论坛！